Introduction of the pneumococcal conjugate vaccine in humanitarian and fragile contexts: Perspectives from stakeholders in four African countries

被引:0
|
作者
Dhaliwal, Baldeep K. [1 ]
Weeks, Rose [1 ]
Huber, Jasmine [1 ]
Fofana, Aminata [1 ]
Bobe, Mohamed [2 ]
Mbailamen, Antoinette Demian [3 ]
Legge, George [4 ,5 ]
Cisse, Gassim [5 ]
Shet, Anita [1 ]
机构
[1] Johns Hopkins Bloomberg Sch Publ Hlth, Int Vaccine Access Ctr, Dept Int Hlth, 415 N Washington St 535, Baltimore, MD 21231 USA
[2] Somalia Somaliland Country Off, Save Children, Mogadishu, Somalia
[3] Minist St Publ, Programme Elargi Vaccinat, Ndjamena, Chad
[4] Expanded Programme Immunisat EPI, Natl Minist Hlth, Juba, Sudan
[5] Expanded Programme Immunisat EPI, Minist Hlth & Publ Hyg, Conakry, Guinea
基金
比尔及梅琳达.盖茨基金会;
关键词
Pneumonia; pneumococcal conjugate vaccine; fragile contexts; health policy; decision-making;
D O I
10.1080/21645515.2024.2314828
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Childhood pneumonia causes a significant burden of preventable child morbidity and mortality in Chad, Guinea, Somalia/Somaliland, and South Sudan. Leaders from these countries have committed to reducing this burden and are preparing to introduce the pneumococcal conjugate vaccine (PCV) into their immunization programs. To support long-term sustainability for expected PCV introductions in settings afflicted by prolonged humanitarian crises this research explores national stakeholders' perspectives on contextual factors that may influence optimal vaccine implementation. This qualitative study used purposive sampling to identify and interview stakeholders involved in vaccine decision-making. Interview transcripts were analyzed through the framework method, an approach involving charting data into pre-populated matrices. Findings from interviews with 16 key informants from government, partner organizations, and international health agencies fit within the following four overarching themes: (1) population-level vulnerabilities to pneumonia, exacerbated by climatic risks and low levels of maternal education; (2) disease burden and the interest in enhancing surveillance to monitor vaccine impact and integrate disease control efforts; (3) policy processes, including formalizing vaccine decision-making; and (4) vaccine implementation preparation, including the conduct of robust communication campaigns, training, and cold chain upgrades. This research explores perspectives from leaders in these countries which are at pivotal moments in their journeys toward introducing PCV. Widespread commitment among leaders, in addition to financial support, will facilitate vaccine introduction. Further, fostering a shared understanding among partners about context-specific determinants of program success will help build tailored implementation strategies for each country.
引用
收藏
页数:9
相关论文
共 42 条
  • [31] Re-evaluating the impact and cost-effectiveness of pneumococcal conjugate vaccine introduction in 112 low-income and middle-income countries in children younger than 5 years: a modelling study
    Chen, Cynthia
    Ang, Gregory
    Akksilp, Katika
    Koh, Jemima
    Scott, Anthony G.
    Clark, Andrew
    Jit, Mark
    LANCET GLOBAL HEALTH, 2024, 12 (09): : e1485 - e1497
  • [32] Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged <5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine — Kenya, 2009–2010
    Miwako Kobayashi
    Laura M. Conklin
    Godfrey Bigogo
    Geofrey Jagero
    Lee Hampton
    Katherine E. Fleming-Dutra
    Muthoni Junghae
    Maria da Gloria Carvalho
    Fabiana Pimenta
    Bernard Beall
    Thomas Taylor
    Kayla F. Laserson
    John Vulule
    Chris Van Beneden
    Lindsay Kim
    Daniel R. Feikin
    Cynthia G. Whitney
    Robert F. Breiman
    BMC Infectious Diseases, 17
  • [33] Meningococcal carriage 7 years after introduction of a serogroup A meningococcal conjugate vaccine in Burkina Faso: results from four cross-sectional carriage surveys
    Mbaeyi, Sarah
    Sampo, Emmanuel
    Dinanibe, Kambire
    Yameogo, Issaka
    Congo-Ouedraogo, Malika
    Tamboura, Mamadou
    Sawadogo, Guetawende
    Ouattara, Kalifa
    Sanou, Mahamadou
    Kiemtore, Tanga
    Dioma, Gerard
    Sanon, Barnabe
    Somlare, Hermann
    Kyetega, Augustin
    Ba, Absatou Ky
    Ake, Flavien
    Tarbangdo, Felix
    Aboua, Frederic Acho
    Donnou, Yvette
    Kamate, Idrissa
    Patel, Jaymia C.
    Schrilink, Susanna
    Spiller, Michael W.
    Topaz, Nadav
    Novak, Ryan
    Wang, Xin
    Bicaba, Brice
    Sangare, Lassana
    Ouedraogo-Traore, Rosmata
    Kristiansen, Paul A.
    LANCET INFECTIOUS DISEASES, 2020, 20 (12): : 1418 - 1425
  • [34] Clonal distribution of invasive pneumococcal isolates from children and selected adults in the United States prior to 7-valent conjugate vaccine introduction (vol 41, pg 4149, 2003)
    Gertz, RE
    McEllistrem, MC
    Boxrud, DJ
    Li, ZY
    Sakota, V
    Thompson, TA
    Facklam, RR
    Besser, JM
    Harrison, LH
    Whitney, CG
    Beall, B
    JOURNAL OF CLINICAL MICROBIOLOGY, 2005, 43 (02) : 1013 - 1013
  • [35] Pneumococcal carriage and antibiotic susceptibility patterns from two cross-sectional colonization surveys among children aged &lt; 5 years prior to the introduction of 10-valent pneumococcal conjugate vaccine - Kenya, 2009-2010
    Kobayashi, Miwako
    Conklin, Laura M.
    Bigogo, Godfrey
    Jagero, Geofrey
    Hampton, Lee
    Fleming-Dutra, Katherine E.
    Junghae, Muthoni
    Carvalho, Maria da Gloria
    Pimenta, Fabiana
    Beall, Bernard
    Taylor, Thomas
    Laserson, Kayla F.
    Vulule, John
    Van Beneden, Chris
    Kim, Lindsay
    Feikin, Daniel R.
    Whitney, Cynthia G.
    Breiman, Robert F.
    BMC INFECTIOUS DISEASES, 2017, 17
  • [36] Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13 valent pneumococcal conjugate vaccine introduction
    François Angoulvant
    Robert Cohen
    Catherine Doit
    Annie Elbez
    Andreas Werner
    Stéphane Béchet
    Stéphane Bonacorsi
    Emmanuelle Varon
    Corinne Levy
    BMC Infectious Diseases, 15
  • [37] Trends in antibiotic resistance of Streptococcus pneumoniae and Haemophilus influenzae isolated from nasopharyngeal flora in children with acute otitis media in France before and after 13 valent pneumococcal conjugate vaccine introduction
    Angoulvant, Francois
    Cohen, Robert
    Doit, Catherine
    Elbez, Annie
    Werner, Andreas
    Bechet, Stephane
    Bonacorsi, Stephane
    Varon, Emmanuelle
    Levy, Corinne
    BMC INFECTIOUS DISEASES, 2015, 15 : 1 - 8
  • [38] Pediatric Bacterial Meningitis Surveillance in Nigeria From 2010 to 2016, Prior to and During the Phased Introduction of the 10-Valent Pneumococcal Conjugate Vaccine (vol 69, pg S81, 2019)
    Tagbo, B. N.
    Bancroft, R. E.
    Fajolu, I
    CLINICAL INFECTIOUS DISEASES, 2020, 70 (05) : 993 - 993
  • [39] Invasive pneumococcal disease in children 5 years after conjugate vaccine introduction - Eight states, 1998-2005 (Reprinted from MMWR, vol 57, pg 144-148, 2008)
    Reingold, A.
    Hadler, J.
    Farley, M. M.
    Harrison, L.
    Lynfield, R.
    Lexau, C.
    Bennett, N.
    Thomas, A.
    Craig, A. S.
    Smith, P. J.
    Beall, B.
    Whitney, C. G.
    Moore, M.
    Pilishvili, T.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2008, 299 (11): : 1253 - 1255
  • [40] Impact of 10-valent Pneumococcal Conjugate Vaccine (PCV10) on nasopharyngeal carriage in children 2 years of age: Data from a four-year time series cross-sectional study from Pakistan
    Nisar, Muhammad Imran
    Shahid, Shahira
    Muhammad, Sajid
    Khalid, Farah
    Hussain, Amjad
    Ahmed, Sheraz
    Shakoor, Sadia
    Kabir, Furqan
    Hotwani, Aneeta
    Ali, Asad
    Zaidi, Anita K. M.
    Omer, Saad B.
    Jehan, Fyezah
    Iqbal, Najeeha
    DATA IN BRIEF, 2021, 35